2,891 research outputs found
Intellectual Capital Performance and Cash-Based Incentive Payments: Impact of Remuneration Committee and Corporate Governance Features
We use a sample of 964 executive directors representing 354 Singapore publicly listed firms to examine linkage between firm performance and cash-based bonus payments. As a pooled OLS regression model may hide different models that characterize subsets of observations we use latent class analysis to further examine the data and to identify more specifically the influence of corporate governance features. Our latent class analysis results indicate that remuneration committees with members having their interests better aligned with shareholders (such as presence of a significant owner) appear more likely to consider the incremental value of tying executive director compensation to intellectual capital performance. Remuneration committees with a lower risk of influence from managerial power were also found to be more likely to support a compensation linkage for executive directors to intellectual capital performance. The influence of the remuneration committee features is evident for both entrepreneurial and traditional firms. Overall, our findings are consistent with both the optimal-contract pricing and managerial power views of executive compensation setting
Recommended from our members
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.
In acute myeloid leukaemia (AML), the cell of origin, nature and biological consequences of initiating lesions, and order of subsequent mutations remain poorly understood, as AML is typically diagnosed without observation of a pre-leukaemic phase. Here, highly purified haematopoietic stem cells (HSCs), progenitor and mature cell fractions from the blood of AML patients were found to contain recurrent DNMT3A mutations (DNMT3A(mut)) at high allele frequency, but without coincident NPM1 mutations (NPM1c) present in AML blasts. DNMT3A(mut)-bearing HSCs showed a multilineage repopulation advantage over non-mutated HSCs in xenografts, establishing their identity as pre-leukaemic HSCs. Pre-leukaemic HSCs were found in remission samples, indicating that they survive chemotherapy. Therefore DNMT3A(mut) arises early in AML evolution, probably in HSCs, leading to a clonally expanded pool of pre-leukaemic HSCs from which AML evolves. Our findings provide a paradigm for the detection and treatment of pre-leukaemic clones before the acquisition of additional genetic lesions engenders greater therapeutic resistance
Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies.
Purpose To evaluate the impact of baseline retinal capillary nonperfusion (RNP) and macular retinal capillary nonperfusion (MNP) status on outcomes at week 24 (W24). Design Post hoc analyses of 2 phase 3, randomized, double-masked, multicenter, sham-controlled studies. Participants Three hundred sixty-six patients with macular edema secondary to central retinal vein occlusion randomized in COPERNICUS and GALILEO. Methods We randomized patients 3:2 to receive intravitreal aflibercept 2 mg every 4 weeks or sham injections until W24. RNP and MNP were assessed by a masked independent reading center. Main Outcome Measures Proportion of patients with 10 disc areas (DA) or more of RNP and any degree of MNP at W24, relative risks of 10 DA or more of RNP or any degree of MNP at W24 developing, change from baseline in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) by baseline RNP and MNP status, and relationship between baseline RNP and MNP status. Results At baseline, 24.6% of patients showed 10 DA or more of RNP and 72.6% showed MNP, regardless of baseline RNP status. At W24, the pooled proportions of patients in the intravitreal aflibercept and sham groups with 10 DA or more of RNP were 11.6% and 29.0%, respectively (P = 0.0001); the respective proportions with any degree of MNP were 61.2% and 79.5% (P = 0.0008). Relative risks and 95% confidence intervals for intravitreal aflibercept versus sham were 0.4 (0.25–0.62) for 10 DA or more of RNP and 0.8 (0.68–0.90) for MNP, indicating a lower risk for these outcomes with intravitreal aflibercept than with sham. Mean BCVA change was greater in intravitreal aflibercept- versus sham-treated eyes, with less than 10 DA and 10 DA or more of RNP at baseline (+17.5 vs. +0.8 letters and +18.3 vs. −4.1 letters, respectively) and with and without baseline MNP (+15.7 vs. +0.3 letters and +17.1 vs. +0.4 letters, respectively). Agreement between baseline RNP and MNP status was low (κ = 0.12). The proportions of patients with 1 or more ocular serious adverse event in the intravitreal aflibercept- and sham-treated groups, respectively, were 3.2% and 11.3%. Conclusions At W24, visual and anatomic improvements, including perfusion status, were greater in eyes treated with intravitreal aflibercept than in eyes treated with sham, regardless of baseline RNP or MNP status
Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies
Purpose To evaluate the impact of intravitreal aflibercept (EYLEA, Regeneron Pharmaceuticals, Tarrytown, NY) versus laser on progression of diabetic retinopathy (DR) severity in Intravitreal Aflibercept Injection in Vision Impairment due to DME (VIVID-DME) and Study of Intravitreal Aflibercept Injection in Patients with Diabetic Macular Edema (VISTA-DME). Design Secondary and exploratory analyses of 2 phase 3, randomized, controlled studies. Participants All patients with a baseline Diabetic Retinopathy Severity Scale (DRSS) score based on fundus photograph (full analysis), patients who progressed to proliferative DR (PDR) (safety analysis) in VIVID-DME (n = 403) and VISTA-DME (n = 459), or both. Methods We randomized patients with diabetic macular edema (DME) to intravitreal aflibercept 2 mg every 4 weeks (2q4), intravitreal aflibercept 2 mg every 8 weeks after 5 initial monthly doses (2q8), or macular laser photocoagulation at baseline and sham injections at every visit. Main Outcome Measures Proportions of patients with 2-step or more and 3-step or more improvements from baseline in DRSS score, who progressed to PDR, and who underwent panretinal photocoagulation (PRP). Results Among patients with an assessable baseline DRSS score, most showed moderately severe or severe nonproliferative DR. The proportions of patients treated with 2q4, 2q8, and laser with a 2-step or more improvement in DRSS score at week 100 were 29.3%, 32.6%, and 8.2%, respectively, in VIVID-DME and 37.0%, 37.1%, and 15.6%, respectively, in VISTA-DME; the proportions with a 3-step or more improvement in DRSS score were 7.3%, 2.3%, and 0%, respectively, and 22.7%, 19.9%, and 5.2%, respectively. Fewer patients in the 2q4 and 2q8 groups versus the laser group progressed to PDR at week 100 in VISTA-DME (1.5% and 2.2% vs. 5.3%) and VIVID-DME (3.2% and 2.0% vs. 12.3%). The proportions of patients who underwent PRP were 2.9%, 0.7%, and 4.5%, respectively, in VIVID-DME and 1.9%, 0.7%, and 5.2%, respectively, in VISTA-DME. The most frequent serious ocular adverse event at week 100 was cataract (pooled intravitreal aflibercept, 1.7% of patients; laser, 3.5% of patients). Conclusions These analyses demonstrate the benefit of intravitreal aflibercept over laser with respect to DR progression, suggesting a benefit on DME, and on underlying DR
The Vehicle, Fall 1982
Vol. 24, No. 1
Table of Contents
Winter SurveillanceB.L. Davidsonpage 3
The InvitationBecky Lawsonpage 4
Check In, Check OutSteve Sandstrompage 4
On The Front Porch StepKeila Tooleypage 5
Old Greek ManDevon Flesorpage 5
Exotic PassionsBecky Lawsonpage 6
PhotographLisa Owenspage 7
Beyond The ThornsBrook Wilsonpage 8
Ritual Of HeatB.L. Davidsonpage 11
The GamerBecky Lawsonpage 12
It\u27s OverKeila Tooleypage 13
DreamJohn Stockmanpage 14
Silver DollarGina J. Grillopage 15
The DancerJessica Lewispage 16
Snapshots Of Rural IllinoisIsabel M. Parrottpage 16
The Last SeasonTheresa Whitesidepage 17
DrawingKaren Haneypage 17
Rotary LuncheonJessica Lewispage 18
Factory TourLinda Fraembspage 18
The ImmigrantsD.L. Lewispage 19
At Shedd AquariumLinda Fraembspage 20
The GuardianBecky Lewispage 20
Digital LifeEverett Tackettpage 21
Full ServiceScott Graypage 22
Dust ShowLinda A. Brownpage 23
At SixMaureen Foertschpage 24
DrawingJean Imherrpage 24
ReflectionMaggie Kennedypage 25
Cat DefiningBecky Lawsonpage 26
Ode To An Unread NewspaperLinda Fraembspage 26
GumSteve Sandstrompage 27
The DancerChrystal Clarkpage 27
PoemD.L. Lewispage 28
For LucyStacey Flanniganpage 29
An AbortionDevon Flesorpage 29
ReveriesKeila Tooleypage 30
Sunday Morning After Tequila With LemonScott Graypage 33
Staging A Living Jewel BoxMichelle Mitchellpage 34
The Other WomanStacey Flanniganpage 35
The Natural LookMichelle Mitchellpage 35
Poem To A Girl Named SandalsJohn Stockmanpage 36
PhotographLisa Owenspage 37
In The Balcony Of The Bijou On A Saturday NightScott Graypage 38
The Canadian Soccer PlayerBecky Lawsonpage 39
The HealingJohn Stockmanpage 39
AppeasedDevon Flesorpage 40
CodaJohn Stockmanpage 40https://thekeep.eiu.edu/vehicle/1040/thumbnail.jp
The Maunakea Spectroscopic Explorer Book 2018
(Abridged) This is the Maunakea Spectroscopic Explorer 2018 book. It is
intended as a concise reference guide to all aspects of the scientific and
technical design of MSE, for the international astronomy and engineering
communities, and related agencies. The current version is a status report of
MSE's science goals and their practical implementation, following the System
Conceptual Design Review, held in January 2018. MSE is a planned 10-m class,
wide-field, optical and near-infrared facility, designed to enable
transformative science, while filling a critical missing gap in the emerging
international network of large-scale astronomical facilities. MSE is completely
dedicated to multi-object spectroscopy of samples of between thousands and
millions of astrophysical objects. It will lead the world in this arena, due to
its unique design capabilities: it will boast a large (11.25 m) aperture and
wide (1.52 sq. degree) field of view; it will have the capabilities to observe
at a wide range of spectral resolutions, from R2500 to R40,000, with massive
multiplexing (4332 spectra per exposure, with all spectral resolutions
available at all times), and an on-target observing efficiency of more than
80%. MSE will unveil the composition and dynamics of the faint Universe and is
designed to excel at precision studies of faint astrophysical phenomena. It
will also provide critical follow-up for multi-wavelength imaging surveys, such
as those of the Large Synoptic Survey Telescope, Gaia, Euclid, the Wide Field
Infrared Survey Telescope, the Square Kilometre Array, and the Next Generation
Very Large Array.Comment: 5 chapters, 160 pages, 107 figure
Azimuthal Angle Correlations for Rapidity Separated Hadron Pairs in d+Au Collisions at sqrt(s_NN) = 200 GeV
We report on two-particle azimuthal angle correlations between charged
hadrons at forward/backward (deuteron/gold going direction) rapidity and
charged hadrons at mid-rapidity in deuteron-gold (d+Au) and proton-proton (p+p)
collisions at sqrt(s_NN) = 200 GeV. Jet structures are observed in the
correlations which we quantify in terms of the conditional yield and angular
width of away side partners. The kinematic region studied here samples partons
in the gold nucleus carrying nucleon momentum fraction x~0.1 to x~0.01. Within
this range, we find no x dependence of the jet structure in d+Au collisions.Comment: 330 authors, 6 pages text, 4 figures, no tables. Submitted to Phys.
Rev. Lett. Plain text data tables for the points plotted in figures for this
and previous PHENIX publications are (or will be) publicly available at
http://www.phenix.bnl.gov/papers.htm
System Size and Energy Dependence of Jet-Induced Hadron Pair Correlation Shapes in Cu+Cu and Au+Au Collisions at sqrt(s_NN) = 200 and 62.4 GeV
We present azimuthal angle correlations of intermediate transverse momentum
(1-4 GeV/c) hadrons from {dijets} in Cu+Cu and Au+Au collisions at sqrt(s_NN) =
62.4 and 200 GeV. The away-side dijet induced azimuthal correlation is
broadened, non-Gaussian, and peaked away from \Delta\phi=\pi in central and
semi-central collisions in all the systems. The broadening and peak location
are found to depend upon the number of participants in the collision, but not
on the collision energy or beam nuclei. These results are consistent with sound
or shock wave models, but pose challenges to Cherenkov gluon radiation models.Comment: 464 authors from 60 institutions, 6 pages, 3 figures, 2 tables.
Submitted to Physical Review Letters. Plain text data tables for the points
plotted in figures for this and previous PHENIX publications are (or will be)
publicly available at http://www.phenix.bnl.gov/papers.htm
Improved Measurement of Double Helicity Asymmetry in Inclusive Midrapidity pi^0 Production for Polarized p+p Collisions at sqrt(s)=200 GeV
We present an improved measurement of the double helicity asymmetry for pi^0
production in polarized proton-proton scattering at sqrt(s) = 200 GeV employing
the PHENIX detector at the Relativistic Heavy Ion Collider (RHIC). The
improvements to our previous measurement come from two main factors: Inclusion
of a new data set from the 2004 RHIC run with higher beam polarizations than
the earlier run and a recalibration of the beam polarization measurements,
which resulted in reduced uncertainties and increased beam polarizations. The
results are compared to a Next to Leading Order (NLO) perturbative Quantum
Chromodynamics (pQCD) calculation with a range of polarized gluon
distributions.Comment: 389 authors, 4 pages, 2 tables, 1 figure. Submitted to Phys. Rev. D,
Rapid Communications. Plain text data tables for the points plotted in
figures for this and previous PHENIX publications are (or will be) publicly
available at http://www.phenix.bnl.gov/papers.htm
Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial
Background
Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy
- …